oral glp 1 agonist GLP-1 receptor promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects Oral Small-Molecule GLP-1 Receptor Agonists:

Studies were excluded if they focused on pediatric populations, only reported emergency procedures, lacked a control group of GLP-1RA nonusers, or used limited International Classification of Diseases, Tenth Revision, and Clinical Modification (ICD-10-CM) codes for aspiration outcomes

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

If Phase 3 trials confirm these results, retatrutide could significantly shift the treatment paradigm

The promise of new and advanced GLP-1 therapies is encouraging with new products speculated to enter the market as soon as mid 2023

Weight loss remains a central therapeutic driver: A reduction in body weight of at least 7 to 10 percent resolves NASH in approximately 65 to 90 percent of patients

While not approved to treat these conditions, in a clinical trial, people who dieted, exercised and took Zepbound for the treatment of obesity or overweight with weight-related medical problems observed changes in cholesterol and reductions in blood pressure and waist size